Advanced searches left 3/3

Carcinoma In Situ - Europe PMC

Summarized by Plex Scholar
Last Updated: 10 September 2022

* If you want to update the article please login/register

Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.

Importance Pathologic complete response after neoadjuvant chemotherapy in breast cancer has been strongly correlated with overall survival and has become the common end point in neoadjuvant trials. The aim of this study was to determine standards for the determination of pathologic complete response in surgical specimens after neoadjuvant chemotherapy for breast cancer with survival endpoints. In the I-SPY2 trial, an adaptive neoadjuvant platform trial for patients with breast cancer at a high risk of recurrence, the study team investigated the relationship between residual DCIS after NAC with three-year event-free survival, distant recurrence-free survival, and local-regional recurrence. Adult women diagnosed with stage II/III breast cancer who are at a high risk of recurrence are among I-SPY2 participants, who are also adult women with stage II/III breast cancer in a young age. The study team found 933 I-SPY2 participants with complete pathology and follow-up data.

Source link: https://europepmc.org/article/MED/36069821


A Novel Nomogram for Predicting Prognosis and Tailoring Local Therapy Decision for Ductal Carcinoma In Situ after Breast Conserving Surgery.

Purpose: We wanted to investigate the role of nomogram-combined biomarkers, mammographic microcalcification, and inflammatory hematologic determinants in guiding local therapy decisions in ductal carcinoma subgroups with differing ipsilateral breast tumour recurrence risk in two ipsilateral breast tumor recurrence risk in situ subgroups with varying ipsilateral breast tumour recurrence risk in chemom a ension re explorer Methods: Patients with DCIS and breast conserving surgery were enrolled and randomly assigned to a training cohort and a nationally validated cohort between January 2009 and December 2018. Before BCS, 1. 1 was the sole risk factors for IBTR to develop a nomogram, according to multivariate analyses of the training cohort, presence of microinvasion, Ki67 index > 14%, mammographic-clustered fine linear microcalcifications and neutrophil/lymphocyte ratio before BCS. The benefit of WBI was limited to the whole cohort and ER-positive tumours, but not in those with low or high risk. Conclusions: The novel nomogram showed the ability to distinguish the risks of IBTR and locations of IBTR.

Source link: https://europepmc.org/article/MED/36079116


Application of deep learning to identify ductal carcinoma in situ and microinvasion of the breast using ultrasound imaging.

Background The diagnosis and prognosis of breast ductal carcinoma in situ with and without microinvasion are different. The cancer cells are trapped in the duct without penetrating the basement membrane, which is not limited to 1 mm, according to MIC, and the maximum diameter of any major invasive lesion is less than or equal to 1 mm. This review was designed to determine whether deep learning could be used to identify DCIS with MIC on ultrasound images. DCIS in West China Hospital of Sichuan University's DCIS were collected from January 2013 to April 2019 and randomly matched to qualification and internal validation sets, according to the clinical and ultrasound records. The ultrasound images were used to develop a logistic regression plot, according to three experienced breast ultrasound consultants. Conclusions The ability of deep learning can be used to determine the incidence of breast DCIS from ultrasound images.

Source link: https://europepmc.org/article/MED/36060588


Application of deep learning to identify ductal carcinoma in situ and microinvasion of the breast using ultrasound imaging

Background and Prognosis of breast ductal carcinoma in situ with and without microinvasion are different. The cancer cells are trapped in the duct without penetrating the basement membrane, according to MIC, and the maximum diameter of any large invasive lesion is less than or equal to 1 mm. This research was designed to determine DCIS with a MIC on ultrasound images in order to determine DCIS with MIC. Methods 467 consecutive inpatients diagnosed with DCIS in West China Hospital of Sichuan University were enrolled from January 2013 to April 2019 and randomly assigned to qualification and internal validation sets, according to training and internal validation sets. Three experienced breast ultrasound physicians analyzed the ultrasound images to determine a logistic regression model. Conclusions The MIC of breast DCIS can be determined from ultrasound scans by deep learning.

Source link: https://europepmc.org/article/MED/PMC9403599


Metastasis to the Pancreas From Ductal Carcinoma In Situ of Breast Cancer: A Case Report and Review of Literature.

BACKGROUND The bones, the liver, the lung, and the brain are all typical sites of metastatic breast neoplasms. Breast cancer seldom meetsastasizes to the pancreas. However, pancreatic metastasis and primary pancreatic cancer are difficult to distinguish due to their common clinical signs and radiological characteristics. Case study We present a case about a 49-year-old woman who was first diagnosed with left breast ductal carcinoma in June 2008. After 12 years, the patient was admitted to the hospital with jaundice. The pancreatic metastasis is most likely due to breast cancer when a pancreatic lesion is found with a history of breast cancer.

Source link: https://europepmc.org/article/MED/35839106


An insight into the invasion of breast ductal carcinoma in situ based on clinical, pathological and hematological data.

Due to the greatly increased incidence of breast cancer, ductal carcinoma in situ has become a non-negligible component of breast cancers. Methods of Analysis of 389 patients with DCIS or DCIS with invasive ductal carcinoma were reviewed, including the clinical evidence. During invasion, there were differences between DCIS and matched IDC in the invasion group, which were used to investigate changes in the tumor heterogeneity during invasion. Patients in invasion and non-invasion groups were balanced in baseline characteristics, but no statistically significant differences were found for DCIS immunohistochemical indicators. P 0. 003 and SII > 347. 50 odds ratio, 2. 46; CI [1. 35-4. 11]; c = 0. 003 and SII > 347. 50 odds ratio, 2. 46; CI [1. 35-4. 12]; p = 0. 003 and 0. 051; CI [1. 35-4. 12]; p = 0. 003 and CI > 3. 46; CI [1. 35-4. 12]; p = p In contrast to the in-situ ones, Invasion tumor cells have a greater proliferative capacity.

Source link: https://europepmc.org/article/MED/36065403


Utilization of lymph node evaluation at hysterectomy for cervical carcinoma in situ.

Background and objectives This report investigated the use and characteristics of lymph node evaluation at hysterectomy for carcinoma in situ of the uterine cervix. Methods This retrospective cohort analysis examined 7395 patients with cervical carcinoma in situ who underwent hysterectomy from 2016 to 2019. In 4. 6 percent, the Lymph node evaluation at hysterectomy was positive. Conclusion Lymph node evaluation was rarely done for cervical carcinoma in situ, and robotic surgery was associated with increased use of lymph node evaluation.

Source link: https://europepmc.org/article/MED/36036713


Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.

In invasive breast cancer, Tumor-infiltrating lymphocytes are prognostic. However, their prognostic value in ductal carcinoma in situ has been controversial. We used different scoring techniques for TILs in multi-national cohorts of Asian and European women to investigate the prognostic role of TILs in the DCIS outcome. Asian patients were younger, with higher grade, HR negative DCIS lesions, and elevated TIL variables. The spatial arrangement of TILs may be a more accurate predictor of DCIS cases than stromal TILs alone, and TILs may be included in DCIS TILs evaluation guidelines.

Source link: https://europepmc.org/article/MED/36010908


Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ.

In young women, chronic breast carcinoma in situ is unusual and understudied. In a modern cohort of women aged u2264-40 years with DCIS, the aim of this research is to discuss clinicopathologic features, diagnosis, and oncologic outcomes. Patients with DCIS were enrolled from 2006 to 2016, among those diagnosed with stage 0-IV breast cancer in women aged 20 to 46 years old, ranging from 2006 to 2016. Among the 98 patients tested, the median age of diagnosis was 38 years; 36 patients were symptomatic on presentation. Patients were not receiving tamoxifen therapy until 1 year postdiagnosis. Conclusions: A large number of young women with DCIS underwent mastectomy, with or without contralateral prophylactic mastectomy was performed. This highlights the importance of careful examination of treatment options in young women with DCIS.

Source link: https://europepmc.org/article/MED/35960452

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions